For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Tafamidis and Attruby represents a true breakthrough . These groundbreaking therapies https://attr-cm069481.csublogs.com/50081894/major-attr-cm-advance-the-drug-and-attruby-give-hope